Global Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Clinical Trials Market Research Report 2022 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Global Clinical Trials Review, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Global Clinical Trials Review, 2022 provides top line data relating to the clinical trials on Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ).

Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope

• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months

Reasons to Buy

• Assists in formulating key business strategies with regards to investment
• Helps in identifying prominent locations for conducting clinical trials which saves time and cost
• Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
• Supports understanding of trials count and enrollment trends by country in global therapeutics market
• Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
• Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

• Report Guidance
• Publisher Clinical Trials Report Coverage
• Clinical Trials by Region
• Clinical Trials and Average Enrollment by Country
• Clinical Trials by G7 Countries: Proportion of Mucopolysaccharidosis I (Mps I) (Hurler Syndrome ) to Genetic Disorders Clinical Trials
• Clinical Trials by Phase in G7 Countries
• Clinical Trials in G7 Countries by Trial Status
• Clinical Trials by E7 Countries: Proportion of Mucopolysaccharidosis I (Mps I) (Hurler Syndrome ) to Genetic Disorders Clinical Trials
• Clinical Trials by Phase in E7 Countries
• Clinical Trials in E7 Countries by Trial Status
• Clinical Trials by Phase
• In Progress Trials by Phase
• Clinical Trials by Trial Status
• Clinical Trials by End Point Status
• Subjects Recruited Over a Period of Time
• Clinical Trials by Sponsor Type
• Prominent Sponsors
• Top Companies Participating in Mucopolysaccharidosis I (Mps I) (Hurler Syndrome ) Therapeutics Clinical Trials
• Prominent Drugs
• Clinical Trial Profile Snapshots
• Appendix

Companies Mentioned

• Sanofi
• JCR Pharmaceuticals Co Ltd
• BioMarin/Genzyme LLC
• BioMarin Pharmaceutical Inc
• Sangamo Therapeutics Inc
• Altasciences Co Inc
• Eloxx Pharmaceuticals Inc
• Magenta Therapeutics Inc
• Medpace Holdings Inc
• Jupiter Neurosciences Inc

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/t18c1m

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900